BAYER AG (BAYRY)

15.13
0.40 2.72
OTC
Prev Close 14.73
Open 15.00
Day Low/High 14.98 / 15.18
52 Wk Low/High 14.61 / 32.80
Volume 592.75K
Exchange OTC
Shares Outstanding 932.55B
Market Cap 76.11B
Div & Yield N.A. (N.A)
China Pharma Industry Rises to the Occasion as Viagra Patent Expires

China Pharma Industry Rises to the Occasion as Viagra Patent Expires

Pfizer's hard-fought control of the erectile dysfunction drug market in China is about to end, cheering its local rivals

Why Merck (MRK) Stock Is Falling In Pre-Market Trading Today

Why Merck (MRK) Stock Is Falling In Pre-Market Trading Today

Merck (MRK) shares are down in pre-market trading after being downgraded to 'equalweight' by analysts at Morgan Stanley (MS) today.

Why Merck (MRK) Stock Is Higher This Morning

Why Merck (MRK) Stock Is Higher This Morning

Shares of Merck (MRK) are higher after the company announced that it entered into a definitive agreement to sell its Merck Consumer Care business to Bayer (BAYRY) for $14.2 billion.

Why Reckitt Benckiser (RBGLY) Stock Is Lower

Why Reckitt Benckiser (RBGLY) Stock Is Lower

Shares of Reckitt Benckiser (RBGLY) are down after the company said it's no longer in active talks to buy the consumer health unit of Merck & Co. (MRK), although Bayer (BAYRY) has proposed a deal.

Why Bayer (BAYRY) Stock Is Higher This Morning

Why Bayer (BAYRY) Stock Is Higher This Morning

Shares of Bayer (BAYRY) are higher after it was reported that the pharmaceutical and chemicals company is exploring a sale of its $10 billion plastics unit to focus on expanding the health business.

Best Call of 2013: Onyx Pharmaceuticals

Best Call of 2013: Onyx Pharmaceuticals

Shareholders were rewarded with a return of 65%. They should now consider investing in acquirer Amgen. Here's why.

China's Urban Wasteland

China's Urban Wasteland

The offer to pay for a 'next-generation' toilet comes as China grapples with its fast-growing cities and their waste.

The Deal: Bayer Inks Deal With Israel's Compugen

The Deal: Bayer Inks Deal With Israel's Compugen

Tie-up could bring $540 million for Compugen's cancer immunotherapy treatments.

FDA's Flawed Call On Aveo's Tivozanib

FDA's Flawed Call On Aveo's Tivozanib

The FDA has let down renal cancer patients with its Tivozanib decision.

China's Big Bang Theory: We've Gone Green

China's Big Bang Theory: We've Gone Green

The nation's pollution worsened with the incessant explosion of New Year's fireworks, despite what officials say.

Go Slow With Pharma IPOs: KYTHERA, Intercept

Go Slow With Pharma IPOs: KYTHERA, Intercept

Francis Gaskins, president of IPO Desktop, says he's going to sit on the sidelines with KYTHERA and Intercept.

7 Big-Pharma Stocks With Untapped Potential

7 Big-Pharma Stocks With Untapped Potential

Emerging markets' demand, coupled with healthy dividends, boost drugmakers.

Impotence Drugs Keep Golf Going

Impotence Drugs Keep Golf Going

Sponsorships from Viagra, Cialis and Levitra make some players cringe when they should be grateful.

Consumer Safety Sometimes Isn't So Safe

Consumer Safety Sometimes Isn't So Safe

Err on the side of caution when it comes to chemicals in food, drinks, toys and other products.

Indevus Pharma Slides on FDA Delay

Shares sink on news the agency wants more safety data before making a decision on testosterone treatment Nebido.